tirzepatide breast cancer study Weight-loss wonder drug Mounjaro/Zepbound shrinks tumors Weight-loss wonder drug Mounjaro/Zepbound shrinks
Description
Maux de tte
Our primary and urgent care experts provide personalized treatment plans to help you achieve better health
Adults with overweight or obesity taking the once-weekly GIP/GLP-1 receptor agonist tirzepatide achieved a mean weight loss of at least 16% at 72 weeks, according to topline results from the SURMOUNT-1 clinical trial
What are GLPS? And what are the benefits
Tirzepatide (Mounjaro) and semaglutide (Ozempic, Wegovy) are helping some people with obsessive thoughts about food find relief.
